CBD Products - Brazil

Brazil

Brazil is projected to reach a revenue of €194.40m in the CBD Products market by 2024.
The revenue is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 1.20%, leading to a market volume of €206.30m by 2029.
When compared globally, the United States is expected to generate the highest revenue in 2024, amounting to €2,388.00m.
In terms of per person revenues, €20.31 is generated in 2024 in relation to the total population.
Brazil's growing interest in CBD products is driving a surge in the market, positioning the country as a key player in the cannabis industry.

Key regions: Netherlands, Spain, United States, Europe, Australia

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The demand for CBD products in Brazil has been steadily increasing in recent years, reflecting a growing trend towards natural health and wellness products in the country.

Customer preferences: Brazilian consumers are showing a strong preference for CBD products due to their perceived health benefits and therapeutic properties. With an increasing awareness of alternative medicine and holistic health practices, more individuals are turning to CBD as a natural remedy for various ailments. The convenience of purchasing CBD products online has also contributed to their popularity among tech-savvy consumers in Brazil.

Trends in the market: One notable trend in the Brazilian CBD products market is the diversification of product offerings to cater to different consumer needs. Companies are introducing a wide range of CBD-infused products, including oils, tinctures, edibles, skincare products, and even pet treats. This variety allows consumers to choose products that best suit their preferences and lifestyles. Additionally, there is a growing interest in organic and locally sourced CBD products, reflecting a broader trend towards sustainability and ethical consumption in the market.

Local special circumstances: Brazil's regulatory environment plays a significant role in shaping the CBD products market in the country. While CBD is legal for medicinal use in Brazil, strict regulations govern its production and sale. Companies must navigate complex licensing requirements and quality control standards to operate in the market. This regulatory landscape can impact product availability and pricing, influencing consumer choices and market dynamics.

Underlying macroeconomic factors: Economic factors such as disposable income levels and consumer spending habits also influence the CBD products market in Brazil. As the economy continues to recover from recent downturns, consumers are becoming more willing to invest in health and wellness products like CBD. The market is further driven by factors such as urbanization, changing lifestyles, and a growing middle class with an increasing focus on self-care and well-being. These macroeconomic trends create a favorable environment for the growth of the CBD products market in Brazil.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.